Browse by author
Lookup NU author(s): Dr Keith Wu,
Dr Zarif Jabbar-Lopez
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.
Author(s): Wu KCP, Jabbar-Lopez ZK
Publication type: Editorial
Publication status: Published
Journal: Journal of Investigative Dermatology
Print publication date: 01/01/2015
ISSN (print): 0022-202X
ISSN (electronic): 1523-1747
Publisher: Nature Publishing Group